Profile data is unavailable for this security.
About the company
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
- Revenue in DKK (TTM)32.38m
- Net income in DKK-53.82m
- Incorporated1917
- Employees27.00
- LocationBioporto A/STuborg Havnevej 15, St.HELLERUP 2900DenmarkDNK
- Phone+45 45290000
- Fax+45 45290001
- Websitehttps://bioporto.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioretec Oy | 29.14m | -28.26m | 436.82m | 37.00 | -- | 6.84 | -- | 14.99 | -0.1984 | -0.1984 | 0.2047 | 0.4213 | 0.5524 | 1.46 | 3.68 | 105,594.60 | -53.58 | -67.11 | -65.75 | -97.60 | 69.85 | 70.97 | -96.98 | -134.05 | 4.86 | -4.02 | 0.0754 | -- | 32.77 | 19.77 | -56.82 | -- | -- | -- |
| Gentian Diagnostics ASA | 92.68m | -3.80m | 452.29m | 58.00 | -- | 4.58 | 193.86 | 4.88 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Mentice AB | 166.85m | -17.06m | 497.03m | 128.00 | -- | 5.58 | 1,845.95 | 2.98 | -1.01 | -1.01 | 10.03 | 5.30 | 0.8435 | 1.97 | 3.88 | 2,082,557.00 | -8.62 | -7.69 | -17.02 | -13.07 | 87.57 | 83.67 | -10.22 | -10.00 | 0.8586 | -- | 0.0553 | -- | 25.54 | 11.74 | 90.81 | -- | -10.83 | -- |
| Omda AS | 271.68m | 57.57m | 498.64m | 291.00 | 8.57 | 8.75 | 4.83 | 1.84 | 4.27 | 4.27 | 20.44 | 4.18 | 0.5534 | 168.94 | 10.73 | 1,432,536.00 | 12.70 | -4.92 | 16.78 | -6.37 | 92.56 | 90.22 | 22.96 | -9.83 | 1.25 | 2.58 | 0.8487 | -- | 12.30 | 19.83 | 179.30 | -- | -3.93 | -- |
| Senzime AB (publ) | 26.65m | -86.21m | 523.73m | 52.00 | -- | 2.69 | -- | 19.65 | -1.30 | -1.30 | 0.3902 | 2.95 | 0.1045 | 1.34 | 5.80 | -- | -33.80 | -35.69 | -35.58 | -38.00 | 26.75 | -20.59 | -323.45 | -558.68 | 5.85 | -- | 0.0308 | -- | 154.77 | 61.90 | -1.09 | -- | -3.69 | -- |
| Nightingale Health Oyj | 27.25m | -134.69m | 544.99m | 81.00 | -- | 1.22 | -- | 20.00 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Paxman AB (publ) | 148.69m | 15.74m | 576.84m | 94.00 | 36.72 | 6.46 | 20.63 | 3.88 | 1.26 | 1.26 | 11.89 | 7.16 | 1.28 | 2.66 | 6.46 | 2,488,099.00 | 13.59 | -5.08 | 18.38 | -7.76 | 69.47 | 69.38 | 10.59 | -5.07 | 1.76 | -- | 0.1122 | -- | 43.99 | 29.35 | 180.69 | -- | 6.26 | -- |
| OssDsign AB | 77.31m | -77.75m | 595.81m | 48.00 | -- | 4.04 | -- | 7.71 | -1.51 | -1.51 | 1.40 | 2.30 | 0.3907 | 3.60 | 6.62 | 2,452,500.00 | -39.29 | -37.92 | -43.39 | -43.56 | 77.15 | 68.10 | -100.57 | -203.06 | 5.18 | -36.90 | 0.013 | -- | 96.84 | 53.26 | -31.30 | -- | -56.16 | -- |
| Integrum AB | 68.38m | 2.74m | 657.78m | 36.00 | 242.89 | 6.57 | 158.01 | 9.62 | 0.2199 | 0.2199 | 5.55 | 8.13 | 0.6307 | 0.5919 | 3.80 | 2,892,222.00 | 2.53 | 0.7612 | 2.80 | 0.8818 | 87.65 | 83.87 | 4.01 | 1.28 | 3.32 | -- | 0.043 | -- | 40.19 | 35.91 | 212.14 | -- | 127.10 | -- |
| SyntheticMR AB (publ) | 59.67m | 10.29m | 739.19m | 38.00 | 70.98 | 9.37 | 50.93 | 12.39 | 0.3804 | 0.3804 | 2.21 | 2.88 | 0.6719 | -- | 1.58 | 2,455,541.00 | 11.59 | 7.19 | 13.87 | 8.85 | 73.94 | 69.70 | 17.25 | 9.08 | -- | -- | 0.0083 | 21.50 | 30.67 | 13.05 | 70.34 | -7.33 | 27.30 | -- |
| Optomed Oyj | 111.49m | -32.61m | 799.14m | 114.00 | -- | 5.47 | -- | 7.17 | -0.2575 | -0.2575 | 0.8872 | 1.08 | 0.5199 | 1.70 | 3.94 | 131,131.60 | -15.21 | -12.95 | -18.59 | -15.90 | 66.76 | 65.69 | -29.25 | -27.84 | 1.72 | -12.96 | 0.1894 | -- | 3.00 | 3.47 | 18.84 | -- | 7.26 | -- |
| BioPorto A/S | 32.38m | -53.82m | 816.29m | 27.00 | -- | 19.57 | -- | 25.21 | -0.1501 | -0.1501 | 0.0903 | 0.1099 | 0.4132 | 3.66 | 7.33 | 1,044,452.00 | -68.68 | -71.10 | -100.20 | -96.55 | 68.08 | 63.38 | -166.23 | -239.22 | 2.36 | -- | 0.1354 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
| C Rad AB | 300.92m | 31.67m | 914.04m | 89.00 | 29.61 | 4.91 | 24.21 | 3.04 | 1.43 | 1.43 | 13.57 | 8.61 | 1.20 | 4.90 | 3.05 | 5,266,839.00 | 12.69 | 5.09 | 17.96 | 7.02 | 45.14 | 43.12 | 10.61 | 4.86 | 2.43 | -- | 0.0058 | 0.00 | 40.92 | 17.44 | 375.05 | 10.89 | 33.69 | -- |
| Nordhealth As | 272.82m | -82.48m | 939.56m | 395.00 | -- | 2.68 | -- | 3.44 | -1.61 | -1.61 | 5.30 | 11.90 | 0.3561 | -- | 8.25 | 1,059,798.00 | -10.76 | -- | -12.25 | -- | 85.96 | -- | -30.23 | -- | -- | -- | 0.00 | -- | 18.60 | -- | 21.96 | -- | -- | -- |
| ADDvise Group AB (publ) | 969.25m | 72.76m | 956.33m | 620.00 | 26.35 | 3.68 | 6.50 | 0.9867 | 0.5864 | 0.5864 | 7.84 | 4.20 | 0.5506 | 6.73 | 5.52 | 2,365,224.00 | 4.14 | 3.72 | 5.17 | 4.77 | 47.63 | 48.95 | 7.51 | 5.89 | 1.09 | 2.99 | 0.6608 | 0.9405 | 44.30 | 38.62 | 27.62 | -- | 30.35 | -- |
Data as of Jul 01 2024. Currency figures normalised to Bioporto A/S's reporting currency: Danish Krone DKK
0.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 31 Mar 2024 | 715.30k | 0.19% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 114.25k | 0.03% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 73.51k | 0.02% |
| Sydbank A/S (Investment Management)as of 31 May 2024 | 48.08k | 0.01% |
More ▼
Data from 31 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
